Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Whitehawk Therapeutics (Nasdaq: WHWK) announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 3, 2025 at 12:30 PM ET. A live webcast will be available on the company's investor relations website and will be replayable for approximately 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – WHWK
In the Nov 26 session, WHWK gained 6.98%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Executive hire | Positive | -3.4% | Appointment of experienced oncology CMO to support ADC development. |
| Nov 26 | Conference appearance | Neutral | +7.0% | Announcement of CEO fireside chat at Piper Sandler healthcare conference. |
| Nov 11 | Conference appearance | Neutral | +2.3% | Upcoming CEO presentation at Jefferies Global Healthcare Conference in London. |
| Nov 06 | Earnings update | Negative | -6.7% | Q3 2025 results with larger net loss despite stronger cash position. |
| Oct 24 | Scientific data | Positive | -1.6% | Real-world PTK7 expression analysis supporting HWK-007 ADC targeting strategy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent conference and scientific updates often coincided with modest to negative moves, while the Jefferies and Piper Sandler appearance headlines previously saw small gains. Positive R&D or hiring news has not consistently translated into sustained price strength.
Over the last few months, Whitehawk reported a strategic pivot to a preclinical ADC portfolio, highlighted in Q3 2025 earnings on Nov 6 with higher cash balances but wider losses. Scientific data on PTK7 presented on Oct 24 underscored its target strategy, yet drew a slightly negative reaction. Conference participation at Jefferies on Nov 18 and Piper Sandler on Dec 3, plus the CMO appointment on Dec 1, show a focus on visibility and team building, with share moves alternating between modest gains and pullbacks.
Key Terms
antibody drug conjugate medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from
Contact:
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-302626225.html
SOURCE Whitehawk Therapeutics, Inc.